Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melaxin and BCG in Stage IV Malignant Melanoma
NCT00671554Phase 2Terminated
- Sponsor
- Prisma Health
- Start
- Apr 2008
- Primary completion
- Feb 2009
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Melaxin in Malignant Melanoma (MM), sponsored by Prisma Health. Primary endpoint: Safety as Measured by Number of Participants With Unexpected Adverse Events or Unexpected Laboratory Results. Started Apr 2008; status: terminated.
02
Drugs
Melaxin
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00671554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00671554.